Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEBI: PCSK9 Inhibitors in Premature CAD
NCT04613167Unknown
- Sponsor
- University Medical Centre Ljubljana
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of alirocumab and evolocumab in coronary heart disease (CHD) and Hyperlipoproteinemia a (3 arms), sponsored by University Medical Centre Ljubljana. Primary endpoints: Ultrasound functional and morphological properties of the arterial wall and Lp (a) concentration, Concentration of Lp (a) and SNP in the LPA gene and 1 more. Status: unknown.
02
Drugs
alirocumabevolocumab
03
Conditions
coronary heart disease (CHD)Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT04613167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613167.